Bank of America Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $28.00

Hims & Hers Health (NYSE:HIMS) had its price target reduced by analysts at Bank of America from $30.00 to $28.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Bank of America‘s target price points to a potential upside of 25.44% from the company’s current price.

A number of other analysts have also recently weighed in on HIMS. Truist Financial restated a “hold” rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Canaccord Genuity Group set a $32.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 12th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. TD Cowen reduced their target price on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a report on Friday, March 27th. Finally, Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $29.37.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded up $0.03 on Tuesday, hitting $22.32. The company had a trading volume of 20,746,443 shares, compared to its average volume of 32,920,871. The business has a 50-day simple moving average of $23.92 and a 200-day simple moving average of $28.60. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The company has a market cap of $5.09 billion, a PE ratio of -248.40, a PEG ratio of 44.19 and a beta of 2.43. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company’s revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the business earned $0.20 earnings per share. Research analysts expect that Hims & Hers Health will post 0.04 EPS for the current fiscal year.

Insider Activity

In related news, insider Soleil Boughton sold 9,463 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the sale, the insider owned 299,368 shares in the company, valued at approximately $8,981,040. This represents a 3.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the sale, the insider owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. This trade represents a 38.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 204,857 shares of company stock worth $5,285,706 in the last quarter. Insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the company. Binnacle Investments Inc purchased a new stake in Hims & Hers Health in the 3rd quarter worth approximately $28,000. Silicon Valley Capital Partners purchased a new stake in Hims & Hers Health in the 3rd quarter worth approximately $48,000. Flagship Harbor Advisors LLC purchased a new stake in Hims & Hers Health in the 4th quarter worth approximately $28,000. Bogart Wealth LLC lifted its position in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in Hims & Hers Health by 44.7% in the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after buying an additional 283 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Negative Sentiment: Hims & Hers announced and then upsized a private offering of 0.00% convertible senior notes due 2032 to $350 million from the originally planned $300 million, raising concerns about future dilution and the balance sheet. Article Title
• Neutral Sentiment: The company said the capital will help preserve financial flexibility while funding international expansion, infrastructure, and AI platform investments, which could support longer-term growth. Article Title
• Negative Sentiment: Media reports also highlighted investor concern that the move may be tied to the planned Eucalyptus buyout and broader growth initiatives, reinforcing the view that Hims & Hers is leaning on debt to finance expansion. Article Title

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.